Evofem Biosciences Inc

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except par value and share data)

	As of
March 31, 2025 · December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$221	$	-
Restricted cash	888		741
Trade accounts receivable, net	1,149		9,832
Inventories	2,263		1,577
Prepaid and other current assets	1,352		1,459
Total current assets	5,873		13,609
Property and equipment, net	429		458
Operating lease right-of-use assets	52		89
Intangible asset, net (Note 7)	6,487		9,597
Other noncurrent assets	36		36
Total assets	$12,877		$23,789
Liabilities, convertible and redeemable preferred stock and stockholders’ deficit
Current liabilities:
Accounts payable	$11,224		$16,172
Notes - carried at fair value (Note 4)	14,327		14,974
Convertible notes, net - Adjuvant (Note 4)	31,346		30,769
Short term debt	-		135
Accrued expenses	3,243		5,509
Accrued compensation	2,645		3,494
Operating lease liabilities - current	48		82
Derivative liabilities	138		1,359
Contingent liabilities - current (Note 7)	705		592
Other current liabilities	7,178		7,362
Total current liabilities	70,854		80,448
Operating lease liabilities - noncurrent	5		7
Contingent liabilities - noncurrent (Note 7)	6,820		9,809
Total liabilities	77,679		90,264
Commitments and contingencies (Note 7)	-		-
Convertible and redeemable preferred stock, $0.0001 par value, senior to common stock
Series E-1 and F-1 convertible and redeemable preferred stock, 2,300 and 95,000 shares authorized; 2,121 and 2,068 shares of E-1 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively; 26,280 shares of F-1 issued and outstanding at both March 31, 2025 and December 31, 2024	4,785		4,782
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at both March 31, 2025 and December 31, 2024	-		-
Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 113,356,354 shares issued and outstanding at both March 31, 2025 and December 31, 2024	11		11
Additional paid-in capital	829,096		829,026
Accumulated other comprehensive loss	(1,983)		(2,630)
Accumulated deficit	(896,711)		(897,664)
Total stockholders’ deficit	(69,587)		(71,257)
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit	$12,877		$23,789

See accompanying notes to the condensed consolidated financial statements (unaudited).

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.